Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
"Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial"
The glucagon receptor is primarily expressed in the liver but also in the central nervous system, kidney, gastrointestinal tract and pancreas [49, 50]
However, the potentially large target patient population, as well as the increased utilization and high drug costs, are a growing concern for many plan sponsors
In addition to finding the effects on multiple populations and pathophysiological impact of drug mechanisms, the future needs improved cost effective formulation and preparation to make GLP-1RA widely accessible
Research suggests that stopping GLP-1 medications entirely leads to weight regain in the majority of patients
